Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum Sensitive Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT03863860
What this trial is testing

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. 252
Testing effectiveness (Phase 2)UnknownNCT04661696
What this trial is testing

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

Who this might be right for
Ovarian Cancer
Chinese Academy of Medical Sciences 75
Testing effectiveness (Phase 2)Study completedNCT00316173
What this trial is testing

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerNeoplasms, Ovarian
GlaxoSmithKline 77
Large-scale testing (Phase 3)Looking for participantsNCT07564141
What this trial is testing

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Who this might be right for
Platinum-Sensitive Ovarian CancerOvarian Cancer
Genmab 688
Testing effectiveness (Phase 2)Study completedNCT01033123
What this trial is testing

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sanofi 41
Testing effectiveness (Phase 2)Looking for participantsNCT06420973
What this trial is testing

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Who this might be right for
Ovarian CarcinomaFallopian Tube CarcinomaPrimary Peritoneal Carcinoma
Peking University Cancer Hospital & Institute 54
Testing effectiveness (Phase 2)WithdrawnNCT04239014
What this trial is testing

Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Who this might be right for
Ovarian Cancer
AstraZeneca
Testing effectiveness (Phase 2)Looking for participantsNCT03983226
What this trial is testing

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Who this might be right for
Ovarian Cancer RecurrentFallopian Tube CancerPrimary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group 167
Testing effectiveness (Phase 2)Study completedNCT02004093
What this trial is testing

Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hoffmann-La Roche 149
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339553
What this trial is testing

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Who this might be right for
OvariancancerPlatinum-sensitive Recurrent
Peking University Third Hospital 30
Not applicableUnknownNCT03446495
What this trial is testing

An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer

Who this might be right for
Ovarian Cancer
Suriya Yessentayeva 60
Early research (Phase 1)Ended earlyNCT00317434
What this trial is testing

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
University of Alabama at Birmingham 12
Not applicableStudy completedNCT01869400
What this trial is testing

An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
PharmaMar, Spain 83
Testing effectiveness (Phase 2)Study completedNCT00610714
What this trial is testing

AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsOvarian Cancer
AstraZeneca 211
Large-scale testing (Phase 3)Ended earlyNCT00849667
What this trial is testing

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Who this might be right for
Ovarian Cancer
Morphotek 1,100
Testing effectiveness (Phase 2)Ended earlyNCT00247988
What this trial is testing

Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
University of Saskatchewan 38
Testing effectiveness (Phase 2)UnknownNCT01570582
What this trial is testing

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Korean Gynecologic Oncology Group 314
Early research (Phase 1)Study completedNCT00473954
What this trial is testing

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
EGEN, Inc. 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT04938583
What this trial is testing

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer by FIGO StageOvarian Cancer Stage IIIOvarian Cancer Stage IV
CanariaBio Inc. 54
Not applicableApproved For MarketingNCT03079687
What this trial is testing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Who this might be right for
Ovarian Cancer
AstraZeneca
Next Page